Why Selegiline Still Matters
Monoamine oxidase inhibitors are the most effective antidepressants almost no one prescribes. In treatment-resistant depression they deliver roughly a 50% response rate in patients who have already failed two or more prior trials, and in atypical depression (the presentation with mood reactivity, hypersomnia, hyperphagia, leaden paralysis, and rejection sensitivity) they outperform tricyclics. Yet only about 2% of psychiatrists prescribe MAOIs with any regularity. The reasons are cultural, not clinical: fear of hypertensive crisis, fear of serotonin syndrome, the burden of a tyramine-restricted diet, and a reputation forged in an era when the dietary lists were absurdly long and the pharmacology poorly understood.
Selegiline exists to solve exactly that problem. The transdermal patch (Emsam) is the one MAOI you can start on a patient without imposing dietary restrictions, at least at its lowest, fully therapeutic dose. It is FDA-approved for major depressive disorder, delivered through the skin, and engineered around a clever pharmacologic trick: by bypassing the gut and liver, it floods the brain with MAO inhibition while leaving intestinal MAO-A largely intact to keep destroying dietary tyramine. The result is an MAOI with the mechanism of the old drugs and a fraction of their baggage.
This guide is about using that advantage without being lulled by it.
The 6 mg patch is a genuinely low-hassle antidepressant: no diet, a placebo-like side-effect profile, and none of the metabolic and sexual burden that drives patients off the older MAOIs. But the moment you go to 9 or 12 mg, you are prescribing a full, non-selective MAOI, and every classic MAOI rule reasserts itself.
Understand where that line sits, respect it, and Emsam becomes one of the most useful and best-tolerated tools for depression that has failed the usual agents.
A caveat that runs through everything below: Emsam's efficacy data come almost entirely from placebo-controlled trials in general major depression. It has not been studied in the atypical or treatment-resistant populations where oral MAOIs earn their keep, and the doses that would treat true TRD (an oral-equivalent well above the patch's ceiling) can't be reached with the patch anyway. So Emsam is best understood as the accessible on-ramp to MAOI therapy, not as a replacement for phenelzine or tranylcypromine in the genuinely refractory patient.
How to Use Selegiline With Confidence
Let's be honest about why MAOIs sit untouched at the bottom of the algorithm. It isn't that clinicians have weighed the evidence and found them wanting, it's fear. Fear of the phone call at 2 a.m. after a patient ate the wrong cheese. Fear of serotonin syndrome from a co-prescription you didn't catch. Fear that the diet is impossible and the interactions are a minefield. If that's you, this section is for you, and selegiline is the drug that makes the fear tractable.
The Core Insight (and the Core Solution)
The reason MAOIs feel dangerous is that two of their interactions are potentially catastrophic: hypertensive crisis (tyramine or sympathomimetics driving blood pressure to stroke-range levels) and serotonin syndrome (adding a serotonergic drug to an MAOI). Both are real. Both are also entirely preventable with a system.
The solution is to treat MAOI safety not as a matter of vigilance but as a matter of protocol: a short checklist you run once at the start and a small set of rules the patient carries with them.
And here is what makes selegiline the ideal entry point: at the 6 mg patch, the single scariest interaction, dietary tyramine, is off the table. The FDA removed the diet requirement for 6 mg because the pharmacology supports it (more on the mechanism below). You are left managing only the serotonergic and sympathomimetic interactions, which are governed by your prescription pad, not by what the patient orders for dinner. That is a dramatically smaller surface area to control.
The Systematic Approach
Build a one-page interaction and diet sheet, and give it to the patient in writing. This is the single highest-yield thing you can do. It should list, in plain language:
- The drugs that must never be combined (serotonergic antidepressants, dextromethorphan, meperidine, decongestants; more below)
- The instruction to tell every prescriber, dentist, and pharmacist that they are on an MAOI before any new medication
- For 9–12 mg patients only: the tyramine diet (aged cheeses, cured/aged meats, tap/draft beer, fava beans, sauerkraut, marmite, soy sauce in quantity)
- The warning sign of hypertensive crisis: a sudden, severe, "splitting" headache
- Your phone number and what to do in an emergency
Run the washout math before you write the prescription. The most common way to get into trouble is starting an MAOI too soon after a serotonergic drug. Before Emsam:
- Taper and stop the prior antidepressant, then wait at least 2 weeks (5 half-lives) before applying the first patch.
- Fluoxetine is the trap: wait 5 weeks, because of its and norfluoxetine's long half-life.
- Bridge the gap with a benzodiazepine if the patient is struggling.
Establish a blood-pressure baseline and teach home monitoring. MAOIs classically cause orthostatic hypotension, not hypertension, day to day; the crisis is the exception, not the rule. Get a seated and standing BP at baseline, and teach the patient to check at home (sitting, then standing after 2–3 minutes, recording both). This tells you whether to slow your titration.
Consider giving the patient a nifedipine "amulet." Many MAOI experts hand the patient a single 10 mg immediate-release nifedipine to carry, with instructions to bite/chew it only if they develop the crisis headache and can confirm a large BP spike. Its main value is psychological: it converts a terrifying abstraction into a manageable plan, and that reassurance itself improves tolerability and adherence.
Choose the right dose for the right goal. If the patient is diet-averse, interaction-anxious, or you simply want the cleanest possible MAOI trial, stay at 6 mg and keep the dietary freedom. If you need more antidepressant effect and the patient is reliable, you can go to 9 or 12 mg, but you are now running a full MAOI and must implement the diet.
Addressing the Specific Fears
At 6 mg, tyramine is a non-issue: the FDA's own testing had subjects eat pounds of cheddar and blue cheese on the 6 mg patch with only a trivial BP rise. What remains is sympathomimetics (decongestants, stimulants, cocaine), and those are controlled by education and your prescribing. Real hypertensive events in careful practice are genuinely rare; one veteran MAOI prescriber logged a single bad event in over 30 years, and it required a patient massively overdosing on Sudafed.
This is the more important risk with selegiline, and it is 100% a prescribing-side problem. Don't co-prescribe serotonergic agents (SSRIs, SNRIs, clomipramine, meperidine, dextromethorphan, tramadol, triptans without caution), and respect washouts. If you control the med list, you control this risk.
For 6 mg, there is no diet. For 9–12 mg, the modern diet is far shorter than the mythology: fresh mozzarella on a fresh pizza is fine, and the real offenders are aged cheeses, cured/aged meats, draft beer, fava beans, and sauerkraut. Most patients manage it easily once they see the actual, short list.
The 6 mg patch is arguably the most forgiving MAOI for a marginally reliable patient, precisely because dietary indiscretion can't hurt them. The patch also removes the "did I take my pill" problem: you can see it on their skin.
Selegiline is not a dangerous MAOI you have to fear, it is the MAOI designed to remove the fear. The 6 mg patch strips away the diet, the metabolic and sexual side effects, and much of the orthostasis, leaving a well-tolerated antidepressant whose only real cautions live on your prescription pad. Learn the short list of drugs to avoid, run the washout, hand the patient a one-page sheet, and you can offer MAOI-class benefit to patients who would never tolerate, or comply with, the older agents.
Part 1: Indications: Who Is Selegiline For?
FDA-Approved Use
- Major depressive disorder: the transdermal patch (Emsam) only.
Oral selegiline (Eldepryl) is FDA-approved for Parkinson's disease as an adjunct, not for depression; its use for depression at 30–60 mg/day is off-label and never formally approved for that purpose in the US.
The Evidence-Based Clinical Picture
Major depression (patch)
All Emsam registration trials were placebo-controlled; there are no head-to-head trials against other antidepressants. Efficacy appears modest and broadly comparable to other antidepressants. The patch's real selling point is not superior efficacy, it's tolerability and the elimination of the tyramine diet at 6 mg.
The MAOI class's true sweet spots: atypical and treatment-resistant depression
This is where the class shines, but with an important asterisk for the patch:
- Atypical depression (mood reactivity, hypersomnia, hyperphagia, leaden paralysis, rejection sensitivity): MAOIs beat tricyclics; many clinicians favor them here.
- Treatment-resistant depression: MAOIs are a Stage-4 option in standard TRD algorithms, with ~50% response after ≥2 failed TCA trials.
- The asterisk: the Emsam patch has not been studied in either population, and the oral-equivalent dose likely needed for TRD (well above what the patch delivers) can't be reached transdermally. For genuine TRD or atypical depression in a diet-capable patient, an oral MAOI (phenelzine, tranylcypromine) is the better-evidenced choice.
Off-label MAOI-class uses (based on oral MAOIs, not specifically the patch)
Social anxiety disorder (phenelzine has a large effect size across RCTs), panic disorder (especially with comorbid social anxiety), dysthymia, and pilot-level data in PTSD and bulimia. The patch has limited social-anxiety data.
Geriatric depression
Oral selegiline has treated depression successfully in treatment-refractory geriatric patients, useful to know, given how few options remain in that group.
Who Is Selegiline Best For?
- A patient with depression that has failed better-marketed first-line agents, who is MAOI-curious but diet- or interaction-phobic (the 6 mg patch's core niche)
- A patient who can't tolerate the metabolic, sexual, or sedating burden of older MAOIs or of SSRIs/SNRIs
- A patient in whom adherence is uncertain and a visible, once-daily patch helps
- A patient who needs an MAOI trial but whose reliability around a diet you don't fully trust
Who Is a Poor Candidate?
- A patient with genuine treatment-resistant or clearly atypical depression who needs an adequately dosed MAOI: reach for an oral agent
- A patient on multiple serotonergic agents that can't be stopped
- A patient with pheochromocytoma (absolute contraindication) or uncontrolled hypertension
- A patient who cannot or will not observe the diet if you intend to use 9–12 mg
- A patient with significant cardiovascular disease prone to orthostatic events
Match the formulation to the goal. If your goal is "give an MAOI-averse patient the easiest possible MAOI," Emsam 6 mg is purpose-built. If your goal is "rescue a truly refractory depression," Emsam is the wrong tool: its ceiling is too low and its TRD evidence is absent. Don't let the patch's convenience talk you into using it for a job it can't do.
Part 2: Before You Start: Workup and Candidacy
Selegiline requires no routine laboratory monitoring: no drug levels, no blood counts, no ECG (unlike lithium or TCAs). The workup is clinical, and it centers on hemodynamics, the medication list, and patient education.
Baseline Assessment
| Assessment | Why |
|---|---|
| Seated and standing BP + HR | Orthostatic hypotension is the most common problematic MAOI effect; this is your baseline to titrate against |
| Full medication reconciliation | The whole safety of an MAOI lives here: hunt for serotonergic agents, decongestants, tramadol, dextromethorphan, meperidine, triptans, stimulants |
| Washout planning | Calculate the gap from any prior antidepressant (see below) before writing the script |
| Cardiovascular history | CVD raises the stakes of both orthostasis and any hypertensive event |
| Substance-use history | Stimulant, cocaine, and heavy-alcohol use are dangerous with any MAOI |
| Diet and reliability assessment | Determines whether you can safely push to 9–12 mg |
| hCG | In any patient of childbearing potential (limited pregnancy safety data) |
The Washout Rules (Get This Right Before the First Patch)
- From most antidepressants: taper and stop, then wait ≥2 weeks (5 half-lives).
- From fluoxetine: wait 5 weeks (long half-life of fluoxetine and norfluoxetine).
- From vortioxetine: ~2–3 weeks.
- Coming off selegiline before starting a new serotonergic drug: taper over ~2 weeks, then wait another 2 weeks before the new agent (irreversible MAO inhibition means the enzyme must regenerate).
- Bridge the drug-free gap with a benzodiazepine if symptoms are hard to tolerate.
Who Should Not Start
- Pheochromocytoma (absolute)
- Concurrent sympathomimetics that can't be stopped
- Concurrent serotonergic agents that can't be stopped or washed out
- Uncontrolled hypertension; significant cardiovascular disease (relative)
- Inability to observe the diet, if 9–12 mg is intended
Part 3: How to Start and Dose
Formulations
- Emsam transdermal patch: 6 mg/24 h, 9 mg/24 h, 12 mg/24 h. Brand-only (no generic). Applied once daily to intact, dry skin (upper torso, upper thigh, or outer upper arm); rotate the site daily.
- Oral selegiline (Eldepryl): 5 mg tablets. MAO-B selective (and thus diet-free) only at ≤10 mg/day, which is subtherapeutic for depression; depression requires 30–60 mg/day, at which point it becomes non-selective and requires the full MAOI diet. Rarely used for depression; the patch supersedes it for most purposes.
The Dose–Diet Threshold (the Single Most Important Concept)
| Patch dose | Dietary restriction? | Pharmacologic status |
|---|---|---|
| 6 mg/24 h | No | Therapeutic; gut MAO-A preserved to clear tyramine |
| 9 mg/24 h | Yes (standard MAOI diet) | Non-selective inhibition; tyramine risk returns |
| 12 mg/24 h | Yes (standard MAOI diet) | Non-selective inhibition; tyramine risk returns |
6 mg = free. 9 mg and 12 mg = feed carefully.
Note the caveat: naturalistic manufacturer data on ~800 patients taking 9–12 mg without the diet showed no hypertensive problems, but the FDA took the conservative route, and medico-legally you should implement the diet at those doses absent a compelling reason.
Starting and Titrating
- Start at 6 mg/24 h. For most patients this is both the starting and the maintenance dose.
- Titrate slowly, no faster than every 2 weeks, in 3 mg increments, to a maximum of 12 mg/24 h, guided by response and tolerability (chiefly orthostasis).
- Going slow protects against orthostatic hypotension, the main dose-limiting effect.
- Serotonergic and sympathomimetic precautions apply at every dose, including 6 mg. The 6 mg exemption is dietary only; it does not exempt you from the drug-interaction rules.
Dose Equivalence (for Context)
- Emsam 6 mg patch ≈ 20 mg oral selegiline (the transdermal route is more efficient because it bypasses first-pass hepatic metabolism).
- This first-pass bypass is exactly why the patch achieves brain MAO inhibition at a dose low enough to spare gut MAO-A.
Timing
- Apply once daily; a consistent time helps adherence.
- If insomnia develops, remove the patch before bedtime (it need not be worn 24 hours to remain effective, and removing it in the evening blunts the activating effect on sleep).
Part 4: Monitoring: The Schedule
Selegiline's monitoring is refreshingly light. There are no required drug levels, blood counts, or ECGs. What you monitor is hemodynamics, tolerability, adherence to the interaction/diet rules, and the patch site.
| Timepoint | What to check |
|---|---|
| Baseline | Seated + standing BP/HR; full med reconciliation; diet/interaction teaching |
| First 2–4 weeks | Frequent contact (e.g., weekly) during titration: BP, orthostatic symptoms, insomnia, patch-site skin, response |
| Ongoing (each visit) | BP; reinforce diet/interaction counseling; screen for any new prescriptions or OTC use; assess mood response |
| Home monitoring | Teach the patient to check sitting-then-standing BP (2–3 min apart) and record BP + HR |
The Specific Things to Act On
- Symptomatic orthostasis / falls risk: slow the titration, reduce the dose, increase fluids, consider support stockings; fludrocortisone in refractory cases.
- Insomnia: remove the patch before bed.
- Patch-site irritation: rotate the site daily; topical hydrocortisone (let it dry before applying the patch).
- Any sudden severe headache: treat as a possible hypertensive emergency; check BP, and if markedly elevated, activate the emergency plan.
- A new prescription from another provider: re-screen the entire list for serotonergic/sympathomimetic conflicts every single time.
The most important "monitoring" for an MAOI isn't a lab, it's re-checking the medication list at every encounter and any time another clinician gets involved. Make "any new meds, from anyone?" a standing question at every visit. That habit prevents the two interactions that actually hurt people.
Part 5: Side Effects and How to Manage Them
The governing principle for selegiline is the opposite of the story with older MAOIs: at 6 mg, the side-effect profile is essentially placebo-like except for insomnia and patch-site irritation. The patch's whole clinical identity is tolerability: markedly less weight gain, fatigue, sexual dysfunction, and orthostasis than phenelzine or tranylcypromine.
Skin and Patch-Site Irritation (the Most Common Patch-Specific Effect)
Management:
- Rotate the application site every day.
- Apply topical hydrocortisone to the site and let it dry fully before applying the patch.
- Ensure skin is clean, dry, and intact.
Insomnia (the Most Common Non-Skin Effect)
Management:
- Remove the patch before bedtime: the simplest and most effective fix.
- Reassess caffeine and sleep hygiene.
Orthostatic Hypotension
Less problematic with the patch than with oral MAOIs, but still the main dose-limiting hemodynamic effect (a paradoxical reduction in sympathetic outflow can occur with any MAOI).
Management:
- Titrate slowly (the primary prevention).
- Increase fluid intake (aim for good hydration; ~8 glasses of water/day).
- Support/compression stockings.
- Reduce or adjust concurrent antihypertensives.
- Divided timing / dose reduction if needed.
- Fludrocortisone for severe, refractory orthostasis.
- Teach home sitting-to-standing BP checks to guide titration.
The Burdens That Are Notably Reduced vs. Older MAOIs
- Weight gain: minimal (a major advantage over phenelzine).
- Sexual dysfunction: minimal.
- Fatigue/sedation: minimal.
These favorable comparisons are one of the strongest reasons to consider Emsam in a patient who needs MAOI-class benefit but was miserable on, or refused, an older agent.
When a patient tells you they "can't tolerate antidepressants" because of weight gain and sexual side effects, the 6 mg patch is worth naming specifically. Its profile on exactly those two domains is close to placebo, an unusual thing to be able to say about an effective antidepressant.
Part 6: Overdose, Toxicity, and Boxed Warnings
Selegiline carries the antidepressant class boxed warning for suicidality, and the two dangerous emergencies of the MAOI class are shared by the whole class: hypertensive crisis and serotonin syndrome. The patch at 6 mg substantially lowers the hypertensive-crisis risk by removing dietary tyramine as a trigger, but the serotonergic risk is undiminished at any dose.
- Suicidal thoughts and behaviors. Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor accordingly. This is the only FDA boxed warning on the Emsam label.
The MAOI Class Safety Warnings (Not Boxed Warnings)
- Serotonin syndrome (contraindication and warning). With serotonergic agents; such co-administration is contraindicated.
- Hypertensive crisis (contraindication and warning/precaution). With tyramine (relevant at 9–12 mg) and with sympathomimetics (relevant at all doses); the relevant foods and drugs are contraindicated at the doses noted.
- Rare discontinuation phenomenon (class caution). Abrupt MAOI cessation can, uncommonly, trigger an agitated or psychotic delirium, hence taper (see Part 9).
Hypertensive Crisis: Recognition and Management
Warning sign to teach: a sudden, severe, occipital "splitting" headache; possibly palpitations, neck stiffness, sweating, nausea. If the patient can, check BP: a rise of ~40 mmHg over baseline is meaningful.
Acute treatment:
- Nifedipine 10 mg immediate-release: bite/chew and swallow; may repeat in 30 minutes if no relief (the classic patient-carried "amulet").
- Labetalol is used in the emergency setting.
- Chlorpromazine 50 mg is an alternative (sedating; less favored).
- Phentolamine 5–10 mg IV is a first-line agent for MAOI hypertensive crisis in the emergency setting; labetalol and nicardipine are alternatives. Titrate carefully to avoid overshooting into hypotension.
Reassurance point: many patients' pressures normalize on their own during the ER wait; the crisis is frightening but often self-limited once the trigger is removed.
Serotonin Syndrome: Recognition
- Triad of mental-status change, autonomic instability, and neuromuscular hyperactivity (clonus, hyperreflexia, tremor, hyperthermia, agitation).
- This is more common and more severe with MAOIs than with most other antidepressant combinations, which is exactly why the washout and interaction rules are non-negotiable.
Management is emergent: stop the offending agents, provide supportive care and cooling, use benzodiazepines, and give cyproheptadine in significant cases. The ED manages the severe end.
Part 7: Drug Interactions
For selegiline, the interaction list is the drug. Get this right and the medication is safe; get it wrong and you risk the two emergencies above. Note that the serotonergic and sympathomimetic rules apply at 6 mg just as they do at 12 mg; only the dietary tyramine restriction is dose-dependent.
1. Serotonergic Agents: Serotonin Syndrome Risk
Absolutely contraindicated / avoid:
- SSRIs and SNRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, duloxetine, etc.)
- Clomipramine: the most serotonergic TCA, highest risk.
- Meperidine: major risk; a classic fatal interaction.
- Dextromethorphan: hidden in OTC cough/cold products.
- Tramadol, St. John's wort, L-tryptophan.
- Ziprasidone: the one antipsychotic that cannot be combined with an MAOI.
Use only with caution:
- Triptans (theoretical serotonergic additive effect, use with caution)
- Carbamazepine
- Buspirone (theoretical additive risk; limited real-world events)
2. Sympathomimetics: Hypertensive-Crisis Risk (All Doses)
- OTC decongestants: pseudoephedrine, phenylephrine (a major cause of avoidable events; note pseudoephedrine has been reported cardiovascularly safe specifically with the 6 mg patch in controlled data, but the safest counsel remains avoidance/caution).
- Stimulants of abuse: cocaine, amphetamines, MDMA, all can precipitate a hypertensive crisis.
- Excessive alcohol: raises hypertensive risk.
- Prescribed psychostimulants (methylphenidate, dextroamphetamine): historically used cautiously as MAOI augmentation by experts without crises, but this is a specialist maneuver, not routine.
3. Dietary Tyramine: Dose-Dependent
Only the tyramine restriction is dose-dependent; the serotonergic and sympathomimetic rules above apply at every dose. At 6 mg, there is no dietary restriction at all. At 9–12 mg, the standard MAOI diet applies, and the modern, evidence-based list is short.
- Aged cheeses
- Cured, aged, or spoiled meats
- Draft/tap beer
- Fava beans
- Sauerkraut
- Marmite / concentrated yeast extracts
- Soy sauce in quantity
- Fresh mozzarella (e.g., on a freshly made pizza) is safe by modern tyramine testing
4. Anesthesia and Surgery
Flag the MAOI to any surgeon or anesthesiologist well in advance; avoid meperidine and certain vasopressors perioperatively; coordinate on timing.
Agents That CAN Be Combined (with Appropriate Care)
- Bupropion (non-serotonergic)
- Mirtazapine, trazodone, trimipramine, desipramine, and doxepin as an oral hypnotic/antidepressant: reportedly usable in expert hands (note: trazodone and Silenor/doxepin appear on formal contraindication lists yet have real-world safe-use experience; proceed only with caution and expertise). Doxepin/Silenor is often listed as not safe, so do not assume otherwise.
- Benzodiazepines: safe (useful for washout bridging and for adjunctive sleep/anxiety)
- Augmentation with the best evidence: lithium. Also second-generation antipsychotics (except ziprasidone), thyroid (T3), and, cautiously, psychostimulants.
The two questions that prevent almost every MAOI disaster are: "Are you taking anything serotonergic?" and "Are you taking anything for a cold, congestion, or as a stimulant?" Ask both at every visit, ask about OTC products and supplements explicitly, and make sure every other prescriber knows the patient is on an MAOI.
Part 8: Special Populations
Pregnancy
- Limited safety data: MAOIs are an older class and poorly studied in pregnancy. Generally avoided when safer, better-characterized alternatives exist.
- A careful risk/benefit discussion is essential; weigh the danger of untreated depression against sparse fetal-safety data.
Lactation
- Transfer into breast milk is not well characterized. Caution is warranted; individualize the risk/benefit decision in coordination with pediatrics.
Elderly
- Orthostatic hypotension is the dominant concern: falls, ischemia, confusion. Start low, titrate slowly, monitor BP closely.
- The patch's lower orthostatic burden vs. oral MAOIs is a point in its favor here, and oral selegiline has a track record in refractory geriatric depression.
Renal Impairment
- Risk of accumulation and consequent orthostatic hypotension/toxicity; consider dose caution and closer monitoring.
Hepatic Impairment
- Accumulation risk; dose caution and close monitoring. (The patch's first-pass bypass changes hepatic exposure relative to oral, but caution still applies.)
Children and Adolescents
- Not recommended: limited safety/efficacy data, and dietary/interaction compliance is a particular concern in this group. The antidepressant suicidality class warning also applies.
Part 9: Discontinuation
Selegiline is an irreversible MAOI: stopping the drug doesn't restore MAO activity until new enzyme is synthesized, which takes roughly 2 weeks. This shapes both how you stop it and how long the restrictions persist afterward.
- Taper over ~2 weeks rather than stopping abruptly. Abrupt MAOI discontinuation can, rarely, precipitate an agitated or psychotic delirium.
- After the last patch, keep the drug and dietary restrictions in place for another ~2 weeks: the enzyme (and thus the interaction risk) persists after the drug is gone.
- Do not start a new serotonergic antidepressant until that full ~2-week enzyme-recovery window has passed (a fresh washout in the reverse direction).
- Emsam is not established for long-term maintenance beyond the initial treatment phase; reassess the plan as you would with any antidepressant.
The dangerous window with an irreversible MAOI is the two weeks after you stop. Patients (and covering clinicians) often assume that once the patch is off, the rules are off. They are not. Write the stop date and the "restrictions continue until [date + 2 weeks]" date on the same instruction sheet.
Part 10: Selegiline vs. the Alternatives
vs. Oral MAOIs (Phenelzine, Tranylcypromine, Isocarboxazid)
Emsam has a markedly friendlier side-effect profile (less weight gain, sexual dysfunction, sedation, and orthostasis) and, at 6 mg, no diet. But the oral agents have the real efficacy data in atypical and treatment-resistant depression, and they can be pushed to fully therapeutic doses. For a diet-averse or side-effect-sensitive patient, Emsam wins on tolerability; for genuine TRD, the orals win on evidence and dosing headroom.
vs. Oral Selegiline (Eldepryl)
The patch is more efficient (6 mg patch ≈ 20 mg oral) and, crucially, retains dietary freedom at its therapeutic dose, whereas oral selegiline must reach 30–60 mg (non-selective, diet-requiring) to treat depression. The patch essentially obsoletes oral selegiline for depression.
vs. SSRIs/SNRIs
No head-to-head data; efficacy appears broadly similar. MAOIs as a class cause more orthostasis but fewer GI effects; the 6 mg patch specifically causes far less sexual dysfunction and weight gain than SSRIs/SNRIs. The cost of the MAOI, though, is the interaction and (at higher patch doses) dietary vigilance.
vs. Tricyclics
Oral MAOIs may outperform TCAs specifically in atypical depression.
The Honest Limitations of Emsam
- No comparative efficacy data: everything is vs. placebo.
- No data in the populations (atypical, TRD) where MAOIs are most valuable.
- Cost: brand-only and historically expensive (patches were noted at roughly $14–$15 each; verify current pricing/coverage).
What Emsam Uniquely Delivers
The only MAOI you can prescribe without a dietary restriction (at 6 mg), a tolerability profile close to placebo, a visible, once-daily dosing form that aids adherence, and a genuine on-ramp for the many patients (and clinicians) whose "MAOI phobia" has kept an effective drug class off the table.
Mechanism: The Short Version
Selegiline irreversibly inhibits monoamine oxidase, the enzyme that degrades monoamine neurotransmitters. By blocking MAO, selegiline raises synaptic monoamine availability: the antidepressant effect.
- MAO-A metabolizes serotonin, norepinephrine, and (with MAO-B) dopamine, and it is the enzyme chiefly responsible for clearing dietary tyramine in the gut wall.
- MAO-B metabolizes dopamine.
Its selectivity is dose-dependent. At low oral doses (≤10 mg/day) selegiline is MAO-B selective (the Parkinson's use), and being MAO-B selective, it doesn't require a diet. At antidepressant exposures it becomes non-selective, inhibiting MAO-A as well, which is what makes it an effective antidepressant and what, in principle, reintroduces tyramine risk.
The elegance of the patch is anatomical. Transdermal delivery bypasses the gut and first-pass hepatic metabolism, so at 6 mg it achieves the high central MAO-A/B inhibition needed for antidepressant effect while leaving intestinal (gut-wall) MAO-A largely intact. That preserved gut MAO-A continues to break down ingested tyramine before it can reach the circulation, so dietary tyramine can't trigger a pressor response. Push the dose to 9–12 mg and enough gut MAO becomes inhibited that the tyramine safety margin erodes, which is why the diet returns at the higher patches.
The Bedside Cheat Sheet
The master rule
- 6 mg = no diet. 9 & 12 mg = full MAOI diet.
- Serotonergic and sympathomimetic rules apply at ALL doses: only the tyramine diet is dose-dependent.
Starting
- Emsam 6 mg/24 h patch, once daily; rotate site daily. 6 mg is start and usual maintenance.
- Titrate no faster than q2 weeks in 3 mg steps to a max of 12 mg/24 h, guided by orthostasis.
- 6 mg patch ≈ 20 mg oral selegiline.
Before the first patch
- Baseline seated/standing BP + HR; full med reconciliation.
- Washout: ≥2 weeks off prior antidepressant (5 weeks for fluoxetine); bridge with a benzo.
Monitoring
- No routine labs, levels, or ECG. Check BP each visit; teach home sitting-to-standing checks.
- Re-screen the med list at every visit and any time another prescriber is involved.
Side effects
- Skin irritation → rotate site, topical hydrocortisone (dry before applying).
- Insomnia → remove patch before bed.
- Orthostasis → slow titration, fluids, stockings, dose reduction; fludrocortisone if severe.
- Notably minimal weight gain, sexual dysfunction, and fatigue vs. older MAOIs.
Never combine (serotonin syndrome / crisis)
- SSRIs, SNRIs, clomipramine, meperidine, tramadol, dextromethorphan, St. John's wort, L-tryptophan, ziprasidone; decongestants (pseudoephedrine/phenylephrine); cocaine/amphetamines/MDMA.
- Triptans, carbamazepine, and buspirone only with caution.
Emergencies
- Hypertensive crisis: severe "splitting" headache → nifedipine 10 mg IR (bite/chew) as the patient-carried option; in the ED, phentolamine 5–10 mg IV (first-line), or labetalol/nicardipine.
- Serotonin syndrome: clonus/hyperreflexia/hyperthermia/agitation → ED, benzodiazepines, cyproheptadine.
Stopping
- Taper ~2 weeks; keep diet/drug restrictions another 2 weeks after the last patch (irreversible enzyme inhibition).
- No new serotonergic antidepressant until that window passes.
Selegiline doesn't ask you to become an MAOI expert overnight, it asks you to learn one threshold and one short list. Below 6 mg's dietary line, you get an antidepressant with a placebo-like tolerability profile and none of the dietary theater that scared a generation of prescribers away from a genuinely effective drug class. Above it, you get a full MAOI and all the classic rules come back. Keep the serotonergic and sympathomimetic cautions front of mind at every dose, run the washouts, hand the patient a one-page sheet, and re-check the medication list every visit, and Emsam becomes what it was designed to be: the MAOI you can actually reach for, offering an underused mechanism to the patients most likely to have run out of easier options.